JAK inhibitors in systemic juvenile idiopathic arthritis

OBJECTIVE: Systemic juvenile idiopathic arthritis (SJIA) is characterized by excessive and inappropriate production of proinflammatory cytokines. Janus kinase inhibitors (JAKi) can block the downstream pathway of many cytokines. The use of JAKi in SJIA or macrophage activation syndrome (MAS) has onl...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Tingyan, Xia, Yu, Luo, Ying, Yang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157237/
https://www.ncbi.nlm.nih.gov/pubmed/37152309
http://dx.doi.org/10.3389/fped.2023.1134312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157237/
https://www.ncbi.nlm.nih.gov/pubmed/37152309
http://dx.doi.org/10.3389/fped.2023.1134312

Ejemplares similares